Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells.

Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells.

Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and improved therapeutic strategies. Conditioning of tumor cells with chemotherapeutic drug has been shown to enhance the anti-tumor effects of cancer vaccines and adoptive cell ther...

Full description

Bibliographic Details
Main Authors:	Archana Thakur, Lawrence G Lum, Dana Schalk, Asfar Azmi, Sanjeev Banerjee, Fazlul H Sarkar, Ramzi Mohommad
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3501501?pdf=render

Similar Items

Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy
by: Ashiq Masood, et al.
Published: (2011-03-01)

Human EGFR-2, EGFR and HDAC triple-inhibitor CUDC-101 enhances radiosensitivity of GBM cells
by: Cody D Schlaff, et al.
Published: (2015-01-01)

Killing of Sarcoma Cells by Proapoptotic Bcl-XS: Role of the BH3 Domain and Regulation by Bcl-XL
by: Raj. S. Mitra, et al.
Published: (2001-01-01)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
by: Lawrence G. Lum, et al.
Published: (2020-01-01)

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
by: Aboukameel Amro, et al.
Published: (2009-02-01)

Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property [v1; ref status: indexed, http://f1000r.es/15s]
by: Asfar S Azmi, et al.
Published: (2013-06-01)

Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.
by: Bin Bao, et al.
Published: (2012-01-01)

Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents
by: Ramzi M. Mohammad, et al.
Published: (2011-01-01)

Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
by: Bruno Christian Koehler, et al.
Published: (2014-01-01)

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-X<sub>L </sub>and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
by: Al-Katib Ayad, et al.
Published: (2008-02-01)

Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer
by: Ren T, et al.
Published: (2015-06-01)

Amphiregulin Regulates Phagocytosis-Induced Cell Death in Monocytes via EGFR and the Bcl-2 Protein Family
by: Christopher Platen, et al.
Published: (2019-01-01)

EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.
by: Pranav Oberoi, et al.
Published: (2013-01-01)

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines
by: Lawrence G. Lum, et al.
Published: (2020-05-01)

SP101 overcomes the drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
by: Hsu, Ya-Ping, et al.
Published: (2016)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
by: Archana Thakur, et al.
Published: (2021-07-01)

Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness
by: Archana Thakur, et al.
Published: (2021-01-01)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
by: Fushun Fan, et al.
Published: (2021-02-01)

Nad metabolism in developing xenopus laevis embryos (101 ways to kill a tadpole)
by: Williams, G. T.
Published: (1979)

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
by: Li Li, et al.
Published: (2021-01-01)

EGFR and Bcl-2 in gastric mucosa of children infected with Helicobacter pylori
by: Ewa Ryszczuk, et al.
Published: (2016-03-01)

EGFR and Bcl-2 in gastric mucosa of children infected with Helicobacter pylori
by: Ewa Ryszczuk, et al.
Published: (2016-03-01)

Primed for the kill: occupying Bcl-2 to target death in acute myeloid leukaemia
by: Andrew Wei, et al.
Published: (2012-12-01)

Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment.
by: Bin Bao, et al.
Published: (2012-01-01)

Examining the impacts of State Route 101 on wildlife using road kill surveys and remote cameras
by: Snyder, Sara Ann
Published: (2014)

Analytical Validation of a Pan-Cancer Panel for Cell-Free Assay for the Detection of <i>EGFR</i> Mutations
by: Min-Kyung So, et al.
Published: (2021-06-01)

Subcellular localization of TSG101 in the cell
by: Tzung-Cheng Ye, et al.
Published: (2003)

Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells.
by: Dejuan Kong, et al.
Published: (2010-08-01)

miR-21 Exacerbates Cytokine Induced Beta Cell Dysfunction via Inhibition of mRNAs Regulating Beta Cell Identity
by: Ibrahim, Sara Mohommad
Published: (2020)

Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.
by: Dejuan Kong, et al.
Published: (2012-01-01)

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
by: Cragg, Mark S., et al.
Published: (2007)

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
by: Mark S Cragg, et al.
Published: (2007-10-01)

Bystander Host Cell Killing Effects of Clostridium perfringens Enterotoxin
by: Archana Shrestha, et al.
Published: (2016-12-01)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
by: Reut Yosef, et al.
Published: (2016-04-01)

Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells
by: Chi-Hung R. Or, et al.
Published: (2016-12-01)

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
by: Jingye Li, et al.
Published: (2021-08-01)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
by: Anna Richter, et al.
Published: (2021-03-01)

The Expression of TSG101 in Squamous Cell Carcinoma
by: Ching-mei Chen, et al.
Published: (2004)

Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis
by: Yongxing Gong, et al.
Published: (2017-02-01)

HST PanCET Program: A Cloudy Atmosphere for the Promising JWST Target WASP-101b
by: Wakeford, H. R., et al.
Published: (2017)